Psoriasis is a chronic, inflammatory autoimmune skin disease that can affect children, adolescents, and adults. Given the limited number of therapies approved for pediatric psoriasis, treatment of this population is very challenging. Topical corticosteroids are associated with more-frequent and more-severe adverse events in children, and only two biologics, Amgen’s Enbrel and Janssen's Stelara, are approved for pediatric and adolescent psoriasis patients, respectively. Topical corticosteroids continue to dominate in terms of patient share among targeted therapies; biologics, although used in later lines of therapy, are experiencing an increase in patient share, reflecting physicians’ growing acceptance of biological therapy use. The use of conventional systemics appears to be declining, underscoring a growing need for treatments with more-acceptable safety profiles.
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric psoriasis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric psoriasis patients?
- How have biologics such as Cosentyx, Enbrel, Humira, Stelara, Taltz, and Tremfya been integrated into the treatment algorithm?
- What percentage of pediatric psoriasis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of pediatric psoriasis patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated patients?
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
- Psoriasis - Current Treatment - Detailed, Expanded Analysis Pediatric Psoriasis - Treatment Algorithms - Claims Data Analysis (US)
Author(s): Mohit Nasa, MBA
Mohit Nasa is a Lead Insights analyst on the Immune and Inflammatory team at Decision Resources Group and has authored content for indications like asthma and rheumatoid arthritis.
He holds a Bachelor’s degree in Pharmacy and has earned his MBA in marketing and CRM from Amity Business School. Prior to joining DRG, Mohit worked as a Senior Business analyst at Novartis where he was responsible for end to end market assessment, reporting analytics and related projects for Novartis’s asthma brand Xolair. Mohit has also worked as Brand Manager at Ozone pharma and an Account Manager for IMS Health.